Idexx Laboratories — Q3 2023 Earnings Presentation

4 slides from Idexx Laboratories's earnings presentation, Nov 1, 2023

Slide 1: IDEXX Q3 2023 Earnings Highlights
IDEXX Q3 2023 Earnings Highlights (NASDAQ: IDXX) Operating Diluted Revenue Profit Earnings Per Share $916M $275M $2.53 Reported growth: +9% 30.1% of Revenue Reported growth: +18% Organic growth: +8% YoY change in basis points: CAG Diagnostics Recurring Reported +100 bps Comparable growth: +16% Organ
Slide 2: 2023 Growth and Financial Performance Outlook
IDEXX Q3 2023 Earnings Highlights (NASDAQ: IDXX) 2023 Growth and Financial Performance Outlook Commentary • Updates 2023 estimates, incorporating strong Q3 financial results and recent US clinical visit trends ◦ Adjusts revenue guidance to $3,635 million - $3,650 million, reflecting 7.9% - 8.4% grow
Slide 3: U.S. Companion Animal Practice Growth Update
U.S. Companion Animal Practice Growth Update As of September 30, 2023 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* 20% 15% 12.2% Practice Revenue 10% 8.2% 6.9% 5.7% 6.0% 6.0% 4.6% 4.3% 4.2% 5% 2.4% 0% 1.8% 2.4% Total Visits 1.2% -0.9%-1.6% -5% -3.2%-
Slide 4: Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice
U.S. Companion Animal Practice Growth Update As of September 30, 2023 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** Q3’2023 + 8.5% + 7.0% Year-Over-Year Growth (%) -2.0% + 0.5% + 8.5% + 7.5% Q3’2022 - 2.0% + 1.0% + 6.0% + 13.5% Q3 Average + 2.5% + 5.0% 2020-2021 + 4.